• Cannabinoid-Based Treatment for Huntington’s Granted Orphan Drug Designation by FDA
  • Vienna to Host RARE2019 Meeting on Rare Diseases
  • Emotional Recognition Defect Linked to Apathy in Huntington’s, Study Shows
  • Researchers Get $6 Million to Continue Work on Huntington’s Stem Cell Therapy
  • Fast Screening Strategy Identifies Potential New Inhibitors for Huntington’s Disease
  • Patients, Family and Friends to Take Part in Variety of Rare Disease Day Events Worldwide
  • Impaired Glial Cell Development Contributes To Huntington’s, Mouse Study Suggests
  • Phase 3 Trial of RG6042 Will Gauge Potential of Gene-silencing Approaches for Huntington’s, Other Diseases
  • Huntington’s Patients in US and Canada Being Enrolled in Phase 3 Study of RG6042
  • FDA Clears First Clinical Study of AMT-130 Gene Therapy in Huntington’s disease
  • Brain Neurons Disconnect from Each Other in Process Called Neuritosis, Mouse Study of Huntington’s Reveals
  • Enrollment Completed for Phase 2 Trial Testing VX15/2503 in Early and Late Prodromal Huntington’s Patients